Intelligence / Healthtech / PMA Approvals / Lung Bioengineering, INC.
Approvalsdevice change approved (PMA)16 Oct 2026
Lung Bioengineering, INC.
16 Oct 2026: Device change approved (PMA) · LungFX Device. Recorded in the openFDA device PMA data.
- Decided
- 16 Oct 2026
- Device
- LungFX Device
- Specialty
- Gastroenterology, Urology
- Type
- Supplement (Normal 180 Day Track No User Fee)
- Reason
- Postapproval Study Protocol
- Reference
- P240033 S002
- Location
- Silver Spring, MD
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Lung Bioengineering, INC.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Lung Bioengineering, INC. in our registers.
More in Gastroenterology, Urology
PMA Approvals
30 OctTraferox Technologies, INC.device change approved (PMA) · TorEx Lung Perfusion System; TorEx Lung PerfusateApprovals30 OctTraferox Technologies, INC.device change approved (PMA) · TorEx Lung Perfusion System; TorEx Lung PerfusateApprovals16 OctLung Bioengineering, INC.device change approved (PMA) · LungFX DeviceApprovals9 OctOrganox Limiteddevice change approved (PMA) · OrganOx metra® SystemApprovals2 OctMedibeacon, INC.device change approved (PMA) · MediBeacon Transdermal GFR SystemApprovals24 SeptProverum, LTD.device change approved (PMA) · ProVee System for BPHApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.